Search This Blog

Tuesday, December 2, 2025

Former EU Foreign Policy Chief Arrested In Fraud Investigation, Homes & Offices Raided

 Former European Commission vice-president and ex-head of the EU's foreign service, Federica Mogherini, has been detained as Belgian authorities investigate alleged misuse of European Union funds, Belgian and French media reports have revealed Tuesday.

Homes and offices are reportedly being raided in connection, though no formal charges were immediately made public for Mogherini. The action includes Belgian police searches at the Brussels headquarters of the European External Action Service (EEAS), which Mogherini led for a half-decade, from 2014 to 2019.

Police were also seen searching offices at the College of Europe in Bruges, where she has served as rector since 2020. The probe is reportedly related to her long stint overseeing the financing of the what serves as an academy for young diplomats.

Federica Mogherini, then head of European Union diplomacy, in 2019. AFP

Another College of Europe employee who serves in an executive office was also detained, as well as top European Commission official Stefano Sannino, who was previously the EEAS secretary-general under Mogherini.

Police have recovered documents said to be related to the three detained officials' potentially criminal activities, based on suspicion of procurement fraud, corruption, and conflicts of interest.

Belgian police confirmed an investigation was ongoing "to assess whether any criminal offences have occurred”, adding: “All persons are presumed innocent until proven guilty by the competent Belgian courts of law."

The case may center on the college's purchase of a building and involves several millions of euros. According to details in The Guardian:

The case is an unprecedented investigation by the European public prosecutor’s office (EPPO), the only EU body that handles criminal cases, which was launched in 2021 to combat cross-border fraud involving EU funds. The EPPO can bring criminal cases in courts in any of the 24 EU member states that have joined it, including Belgium.

The case centres on whether the College of Europe and or its representatives were informed in advance about the tender for a training programme for young diplomats before the official launch of the bidding process.

The EPPO said it had “strong suspicions” that the rules on fair competition had been breached and that confidential information had been shared with one of the candidates taking part in the tender. The College of Europe in Bruges was awarded a contract to run the European Union Diplomatic Academy in 2021-22 after a decision from the EU foreign service. The EPPO said immunity of the three suspects had been lifted at its request.

The arrested officials are suspected of trading in confidential information and breaching fair competition laws.

Via Wiki Commons

Another source reviewing the probe details the following:

The probe reportedly focuses on the college’s €3.2 million ($3.7 million) purchase of a building on Spanjaardstraat in Bruges, in 2022, shortly before receiving €654,000 in funding from the EEAS. Authorities suspect the institution may have had access to confidential information, undermining fair competition. 

An EU diplomat has been cited in The Guardian praising the European public prosecutor’s office as it "is not afraid to go after big names." The diplomat added: "If the allegations are true, they should be severely punished to send a clear message that any type of corruption is not tolerable in the EU."

As for the College of Europe, many of its graduates go on to senior roles within European institutions and political bodies. All of this is certain to spur on suspicion among sectors of the general public that EU elite circles could be a hotbed for corruption, given billions in public funds are constantly doled out and transferred this way and that.

https://www.zerohedge.com/political/former-eu-foreign-policy-chief-arrested-fraud-investigation-homes-offices-raided

'KFF: Medicaid Work Rules Exempt the 'Medically Frail.' Deciding Who Qualifies Is Tricky'

 Eliza Brader worries she soon will need to prove she's working to continue receiving Medicaid health coverage. She doesn't think she should have to.

The 27-year-old resident of Bloomington, Indiana, has a pacemaker and a painful joint disease. She also has fused vertebrae in her neck from a spinal injury, preventing her from turning her head.

Indiana's Medicaid agency currently considers Brader "medically frail," giving her access to an expanded set of benefits, such as physical therapy.

New federal rules will require more than 18 million Medicaid enrollees nationwide to show they're working, volunteering, or going to school for 80 hours a month starting in 2027 to keep their coverage. Brader is exempt as long as she's deemed medically frail.

But lacking sufficient federal guidance, states are wrestling with how to define medical frailty -- a consequential decision that could cut Medicaid coverage for many people, said state officials, consumer advocates, and health policy researchers.

"It's terrifying," Brader said. "I already have fought so hard to get my healthcare."

'Incredibly High' Stakes

President Donald Trump's One Big Beautiful Bill Act slashes nearly $1 trillion from Medicaid over the next decade, with much of the savings projected to come from no longer covering those who don't qualify under the new work rules. Those spending cuts help offset the costs of GOP priorities, such as extra border security and tax cuts that mainly benefit the wealthy.

Conservative lawmakers have argued that Medicaid, the government health insurance program for people with low incomes or with disabilities, has grown too large and expensive, especially in the wake of its expansion to more low-income adults under the Affordable Care Act. They also say that requiring participants to work is common sense.

The work rules in Trump's tax-and-spending law offer exemptions for several groups who might struggle to meet them, including people deemed "medically frail." The law spells out certain "medically frail" conditions such as blindness, disability, and substance use disorder. But it does not list many others.

Instead, the law exempts those with a "serious or complex medical condition," a term whose interpretation could vary by state.

State officials say they need more clarity to ensure that people who cannot work for health reasons retain rightful access to Medicaid. They also worry that, even with a clear definition, people will face the onerous task of having to regularly vouch for being medically frail, which is a challenge without reliable access to medical care.

"The stakes are incredibly high," said Kinda Serafi, a partner at consulting firm Manatt Health in New York City.

The new work requirements will affect Medicaid recipients in 42 states and Washington, D.C. Eight states -- Alabama, Florida, Kansas, Mississippi, South Carolina, Tennessee, Texas, and Wyoming -- did not expand their Medicaid programs to cover additional low-income adults, so they won't have to implement the work rules.

The Medicaid work rules are expected to be the largest driver of health insurance coverage losses over the next decade, according to the nonpartisan Congressional Budget Office.

Forty-four percent of all adults covered by states' expanded Medicaid programs have at least one chronic health condition, according to KFF.

A Challenge for States

State Medicaid agencies are scrambling to implement the rules with little direction from HHS, which has yet to issue specific guidance. Federal officials will clarify the "medically frail" definition next year, said Andrew Nixon, an agency spokesperson.

Ultimately, states will have to decide who is unhealthy enough to be exempt from work rules. And it won't be easy for state workers and their computer systems to track.

Every year, state eligibility systems screen millions of applicants to check if they qualify for Medicaid and other government programs. Now, these same systems must screen applicants and existing enrollees to determine whether they meet the new work rules.

Jessica Kahn, MPH, a partner at consulting firm McKinsey & Co. in Washington, D.C., has urged states to start planning how to adapt eligibility systems to verify work status. States can do a "tremendous amount" of work without direction from the federal government, said Kahn, a former federal Medicaid systems official, who spoke during a recent Medicaid advisory panel hearing. "Time is a-wasting already."

State Medicaid directors are pondering the challenge.

"Medical frailty gets so complex," Emma Sandoe, PhD, MPH, Oregon's Medicaid director, said during a recent panel discussion. Conditions that can keep people from working, such as mental health disorders, can be hard to prove, she said.

A state might try to use data pulled from a person's health records, for instance, to determine medical frailty. But information from a patient's chart may not paint a clear picture of someone's health, especially if they lack regular access to medical care.

It's a tall order for eligibility systems that historically have not had to scrape medical records to screen applicants, said Serafi of Manatt Health.

"That is an incredibly new thing that eligibility enrollment systems are just not fluent in at all," Serafi said.

Lobbying groups for the private health insurance companies that help run Medicaid in many states also have urged federal regulators to clearly define medical frailty so it can be applied uniformly.

In a Nov. 3 letter to federal officials, the Medicaid Health Plans of America and the Association for Community Affiliated Plans advocated for allowing enrollees to qualify for the exemption by saying on their applications that they have conditions that make them medically frail. Successfully implementing exemptions for the medically frail will be "crucial" given the "severe health risks of coverage loss for these populations," the groups said.

Some state officials worry about unintended consequences of the work rules for people with chronic conditions.

Jennifer Strohecker, PharmD, who recently resigned as Utah's Medicaid director, reiterated the high stakes, especially for those with diabetes on Medicaid. They may be very healthy and functional with insulin, but if they fail to complete the work requirements, that may change, Strohecker said during a recent Medicaid advisory hearing.

Whether someone is deemed medically frail already depends heavily on where they live.

For example, in Arkansas, people indicate on their Medicaid applications that they're disabled, blind, or need help with daily living activities.

Approximately 6% of the roughly 221,000 people enrolled in Arkansas' Medicaid expansion program are deemed medically frail, according to Gavin Lesnick, a spokesperson for the Arkansas Department of Human Services.

In West Virginia, the state accepts a medical frailty designation when an applicant self-reports it.

The burden of proof is higher in North Dakota. Applicants there must answer a questionnaire about their health and submit additional documentation, which may include medical chart notes and treatment plans. More than half of applicants were denied last year, according to Health and Human Services Department spokesperson Mindy Michaels.

Indiana's Family and Social Services Administration, which runs its Medicaid program, declined an interview and said it could not comment on individual cases, like Brader's.

Brader worries the additional red tape will cause her to lose Medicaid again. She said she was temporarily kicked off the program in 2019 for failing to meet the state's work rules when Indiana said her work-study job didn't count as employment.

"Anytime I have tried to receive help from the state of Indiana, it has been a bureaucratic nightmare," she said.

As states await federal guidance, Kristi Putnam, a senior fellow at the conservative Cicero Institute and former secretary of the Arkansas Department of Human Services, which oversees the state Medicaid program, said even if a state creates an extensive list of qualifying "medically frail" conditions, the line must be drawn somewhere.

"You can't possibly create a policy for exemptions that will catch everything," she said.

'KFF Health News is a national newsroom that produces in-depth journalism about health issues.'

https://www.medpagetoday.com/publichealthpolicy/medicaid/118767

'GLP-1s should not replace a healthy diet and physical activity, WHO document says'

 

  • The WHO issued new guidelines endorsing GLP-1 receptor agonists for the long-term treatment of obesity in adults.
  • GLP-1 drugs must be combined with counseling on behavioral and lifestyle changes, the WHO emphasized.
  • Widespread, equitable, and affordable access to GLP-1 agents remains a top priority.

GLP-1 receptor agonists for obesity are effective over the long term when paired with lifestyle interventions, but global accessibility must be improved, the World Health Organization (WHO) concluded.

The WHO made two recommendations in its first-ever guideline on GLP-1 agents: The drugs can be used as a long-term (6 months or longer) obesity treatment, based on moderate-certainty evidence, and patients prescribed these agents should receive counseling on behavioral and lifestyle changes, including diet and exercise, based on low-certainty evidence.

The recommended use of GLP-1 therapies, including tirzepatide (Zepbound), semaglutide (Wegovy), and liraglutide (Saxenda), for adults with obesity is "grounded in the recognition of obesity as a chronic, relapsing disease that requires lifelong care," wrote Francesca Celletti, MD, PhD, of the WHO, and colleagues in JAMA.

GLP-1 agonists are "more than a scientific breakthrough," the authors noted. "They represent a new chapter in the gradual conceptual shift in how society approaches obesity -- from a 'lifestyle condition' to a complex, preventable, and treatable chronic disease. This promise of effective treatment can catalyze the broader transformation needed to build an integrated ecosystem that redefines health promotion, disease prevention, and care with a focus on equity."

That being said, they don't replace the need for a healthy diet and physical activity, emphasized WHO Director-General Tedros Adhanom Ghebreyesus, PhD, during a press conference.

"These new medicines are powerful clinical tools offering hope to millions. But let me be clear: medicine alone will not solve the obesity crisis," he said. "Obesity is a complex disease that ... has many social, commercial, and environmental determinants requiring action in many sectors -- not only in the clinic."

"One of the most serious public health challenges of our time," according to Ghebreyesus, obesity affects over 1 billion people worldwide. Last year, there were 3.7 million deaths related to obesity, accounting for 12% of all deaths due to noncommunicable diseases globally.

By 2030, the number of people living with obesity is expected to double to 2 billion globally.

GLP-1 receptor agonists have been FDA approved for over 20 years for type 2 diabetes, and were added to WHO's list of essential medicines for the treatment of diabetes in high-risk groups this past September.

More recently, semaglutide and tirzepatide showed significant weight loss among patients with obesity, leading to FDA approvals for this indication in 2021 and 2023.

Despite their efficacy, there are several barriers to widespread use of GLP-1 drugs, including steep costs, a limited production capacity, and supply-chain constraints. The WHO said implementation of its recommendations rely on three critical factors:

  • Achievement of more widespread and fair access to affordable GLP-1 therapies
  • Readiness of health systems to deliver high-quality obesity care that integrates GLP-1 drugs with behavioral therapy
  • Care that is person-centered, nondiscriminatory, and oriented toward universal access

"Our greatest concern is equitable access," said Ghebreyesus.

Even under the current best projected scenario, production of GLP-1 drugs would only cover around 100 million people -- less than 10% of the worldwide obesity population.

"Without concerted action, these medicines could contribute to widening the gap between the rich and the poor, both between and within countries," said Ghebreyesus. Strategies to improve access include generic production (particularly as the patent for semaglutide expires next year), pooled procurement, tiered pricing, voluntary licensing, and development of more oral formulations, which may help to simplify production, logistics, and storage.

"This guideline is a key part of WHO's acceleration plan to stop obesity," Ghebreyesus added. "It is built on evidence and shaped by the principle of health for all, ensuring that scientific progress benefits everyone, everywhere."

Both recommendations in the guideline are listed as conditional, meaning that the benefits don't clearly outweigh the undesirable outcomes from an individual patient, clinical, and public health perspective.

Celletti and colleagues called out the limited data on long-term efficacy and safety, titration, maintenance, and discontinuation of GLP-1 drugs. When benefits are weighed against the high price tag of most agents, inadequate health system preparedness, and potential equity implications, the scale could be tipped unfavorably, they noted.

There is also low certainty of evidence that intensive behavioral therapy can enhance the weight-loss effects of GLP-1 drugs. Conditionality was also attributed to the variability in patient priorities, potential health equity impacts, and context-specific feasibility, in addition to delivery costs.

The recommendations only apply to adults with obesity, defined as a body mass index of 30 or higher. The guidelines do not mention adults living with overweight and obesity-related comorbidities, for whom GLP-1 agents are also indicated.

This is a "living" guideline, meaning it will be updated as more data become available, the authors said. Guidelines on use of GLP-1 drugs in children with obesity are expected soon.

Disclosures

Celletti reported no disclosures. A co-author reported receiving grants from the Gates Foundation, which provided partial financial support for the development of the guideline.

FDA OKs Blood-Based Test to Help Detect High-Grade Prostate Tumors

 The FDA approved Cleveland Diagnostics' blood-based test to help diagnose high-grade prostate tumors and aid in biopsy decisions, the company announced.

Dubbed IsoPSA, the in vitro diagnostic kit is indicated for men ages 50 and older with an elevated prostate-specific antigen (PSA) level. According to the company, the blood-based test analyzes the PSA isoform composition in blood to better determine whether or not elevated PSA comes from cancer cells.

"As a practicing urologist, I see firsthand how the limitations of current PSA testing can lead to unnecessary procedures and anxiety for patients and appreciate the critical need for early and accurate risk assessment and testing," said Aaron Berger, MD, of Associated Urological Specialists in Chicago, in a statement. "IsoPSA represents a meaningful advancement, giving physicians a tool that improves risk assessment and helps us make more informed biopsy decisions with greater confidence."

Approval was supported by a prospective study conducted at 14 U.S. sites and from multiple validation studies.

A laboratory-developed test (LDT) of IsoPSA has been available since 2020 and is included in the National Comprehensive Cancer Network's prostate cancer early detection guidelines and covered by Medicare for eligible beneficiaries.

Multiple studies have supported the LDT.

In a prospective, multicenter study of 888 men scheduled for prostate biopsy, the IsoPSA LDT demonstrated an area under the receiver operating characteristic curve of 0.783 (95% CI 0.752-0.814) for detecting high-grade tumors. Sensitivity reached 90.2% and specificity was 45.5%, while the negative and positive predictive values were 89.3% and 47.7%, respectively.

real-world observational clinical utility study of the LDT involving 38 providers showed that IsoPSA testing among 900 men ages 50 and up with a PSA of at least 4 ng/mL resulted in a 55% net reduction in recommendations for prostate biopsy.

https://www.medpagetoday.com/urology/prostatecancer/118778